John M. Bennett

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial”.

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

The Lancet Oncology(2021)10.1016/s1470-2045(21)00494-0

N/A

4.0DataRank · unranked

193 citations

Andre C. Schuh, Eytan M. Stein, Pau Montesinos, Andrew H. Wei, Stéphane de Botton +12 more

Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes

Leukemia(2022)10.1038/s41375-022-01724-9

N/A

0.926DataRank · unranked

28 citations

Jan Philipp Bewersdorf, Rena Buckstein, Mikkael A. Sekeres, David P. Steensma, Uwe Platzbecker +44 more

Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997

Journal of Clinical Oncology(2007)10.1200/jco.2006.08.0762

N/A

0.900DataRank · unranked

402 citations

Donna S. Neuberg, Michael R. Grever, Gordon W. Dewald, John M. Bennett, Elisabeth M. Paietta +6 more

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

Blood Advances(2022)10.1182/bloodadvances.2022008747

N/A

0.525DataRank · unranked

11 citations

Omar Abdel-Wahab, Andrew H. Wei, Michael R. Savona, Mina L. Xu, Zhuoer Xie +45 more

Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG‐ACRIN analysis

Cancer(2023)10.1002/cncr.34807

N/A

0.400DataRank · unranked

8 citations

Zhuoxin Sun, Catherine Lai, Hugo F. Fernández, Larry D. Cripe, Rhett P. Ketterling +11 more

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

Blood Reviews(2023)10.1016/j.blre.2023.101128

N/A

0DataRank · unranked

31 citations

Jan Philipp Bewersdorf, Zhuoer Xie, Matteo Giovanni Della Porta, Rami S. Komrokji, Mina L. Xu +43 more

Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer

Cancers(2020)10.3390/cancers12020306

N/A

0DataRank · unranked

23 citations

Margret B. Einarson, John M. Bennett, Anna S. Nikonova, Mohamed Elmekawy, Yan Zhou +4 more

Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

Modern Pathology(2024)10.1016/j.modpat.2024.100615

N/A

0DataRank · unranked

12 citations

Savanah D. Gisriel, Amer M. Zeidan, John M. Bennett, Rafael Bejar, Jan Philipp Bewersdorf +48 more

Assessing sociodemographic and regional disparities in Oncotype DX Genomic Prostate Score uptake

Cancer(2024)10.1002/cncr.35511

N/A

0DataRank · unranked

3 citations

Ekaterina Chirikova, Daphne Y. Lichtensztajn, Serban Negoita, Tamer Aboushwareb, John M. Bennett +16 more